Hagens Berman Sobol Shapiro LLP announced today it has begun an investigation of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for potentially misrepresenting information to shareholders which may have artificially increased stock values. Hagens Berman believes the biopharmaceutical giant violated federal securities laws, specifically the Securities Exchange Act which protects the rights of shareholders.

AMAG Pharmaceuticals may have withheld information pertaining to the company’s primary drug, Feraheme, in the Registration Statement issued on Jan. 21, 2010. More than 3.6 million shares of AMAG common stock sold to the public at a potentially inflated price of $48.25 per share, the law firm believes, thereby raising more than $173 million from its initial public offering.

In mid-February, AMAG's stock fell over $7.00 to close at $38.12 per share after analyst reports indicated that several patients exposed to Feraheme experienced serious adverse reactions and possibly one death.

The law firm believes AMAG’s stock values declined further after reports claimed the company failed to disclose the IPO strategy behind a rebate program. The company might have attempted to front load sales into the fourth quarter which would cause sales to drop off after the initial offering.

If you have information related to AMAG’s failure to disclose adverse reactions to Feraheme in the Registration Statement, you are encouraged to contact attorneys at Hagens Berman at AMAG@hbsslaw.com or to call at 510-725-3000.

Investors who purchased shares of AMAG between Jan. 21, 2010 and March 1, 2010 can move for lead plaintiff but must do so on or before May 18, 2010. To discuss moving for lead plaintiff please contact Peter Borkon at 510-725-3030 or email him at AMAG@hbsslaw.com.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is a consumer-rights class-action law firm with offices in San Francisco, Seattle, Chicago, Boston, Los Angeles, and Phoenix. Since 1993, HBSS continues to successfully fight for consumer rights in large, complex litigation. More about the law firm and its successes can be found at www.hbsslaw.com.